Dynamic contrast-enhanced MRI in clinical trials of antivascular therapies

[1]  T. Curran,et al.  Phase I Study of Vismodegib in Children with Recurrent or Refractory Medulloblastoma: A Pediatric Brain Tumor Consortium Study , 2013, Clinical Cancer Research.

[2]  Chiun Hsu,et al.  Dynamic contrast-enhanced magnetic resonance imaging biomarkers predict survival and response in hepatocellular carcinoma patients treated with sorafenib and metronomic tegafur/uracil. , 2011, Journal of hepatology.

[3]  H. Fine,et al.  A phase II trial of single-agent bevacizumab in patients with recurrent anaplastic glioma. , 2011, Neuro-oncology.

[4]  J. Desai,et al.  Clinical, Pharmacodynamic, and Pharmacokinetic Evaluation of BNC105P: A Phase I Trial of a Novel Vascular Disrupting Agent and Inhibitor of Cancer Cell Proliferation , 2011, Clinical Cancer Research.

[5]  G. Jayson,et al.  A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  J. Hainsworth,et al.  Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial , 2011, The Lancet.

[7]  D. Kerr,et al.  Randomized, placebo-controlled, phase III study of first-line oxaliplatin-based chemotherapy plus PTK787/ZK 222584, an oral vascular endothelial growth factor receptor inhibitor, in patients with metastatic colorectal adenocarcinoma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  A. Santoro,et al.  Phase I and pharmacodynamic study of high-dose NGR-hTNF in patients with solid tumors. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  A. Kiss,et al.  Microbubble ultrasound (DCE-US) compared to DCE-MRI and DCE-CT for the assessment of vascular response to sunitinib in renal cell carcinoma (RCC). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  P. Choyke,et al.  Phase I trial of vandetanib and bevacizumab evaluating the VEGF and EGF signal transduction pathways in adults with solid tumours and lymphomas. , 2011, European journal of cancer.

[11]  J. Marcus,et al.  First-line erlotinib and bevacizumab in patients with locally advanced and/or metastatic non-small-cell lung cancer: a phase II study including molecular imaging. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  A. Tolcher,et al.  A phase I study of MN-029 (denibulin), a novel vascular-disrupting agent, in patients with advanced solid tumors , 2011, Cancer Chemotherapy and Pharmacology.

[13]  G. Giaccone,et al.  Evaluation of KRAS Mutations, Angiogenic Biomarkers, and DCE-MRI in Patients with Advanced Non–Small-Cell Lung Cancer Receiving Sorafenib , 2011, Clinical Cancer Research.

[14]  Geoff J M Parker,et al.  The effect of blood inflow and B1‐field inhomogeneity on measurement of the arterial input function in axial 3D spoiled gradient echo dynamic contrast‐enhanced MRI , 2011, Magnetic resonance in medicine.

[15]  G. J. M. Parker,et al.  A two-part Phase II study of cediranib in patients with advanced solid tumours: the effect of food on single-dose pharmacokinetics and an evaluation of safety, efficacy and imaging pharmacodynamics , 2011, Cancer Chemotherapy and Pharmacology.

[16]  E. Ashton,et al.  Phase 1 First-in-Human Trial of the Vascular Disrupting Agent Plinabulin (NPI-2358) in Patients with Solid Tumors or Lymphomas , 2010, Clinical Cancer Research.

[17]  G. Salles,et al.  Comparison of Single Agent GA101 In Japanese and European Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (B-NHL) – Results From Two Phase I Studies , 2010 .

[18]  A. J. van der Kogel,et al.  Longitudinal magnetic resonance imaging-based assessment of vascular changes and radiation response in androgen-sensitive prostate carcinoma xenografts under androgen-exposed and androgen-deprived conditions. , 2010, Neoplasia.

[19]  Alan Ashworth,et al.  Translating cancer research into targeted therapeutics , 2010, Nature.

[20]  A. Coulthard,et al.  Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent , 2010, British Journal of Cancer.

[21]  A. Padhani,et al.  Multiparametric imaging of tumor response to therapy. , 2010, Radiology.

[22]  G. Hutchins,et al.  Pancreatic cancer: utility of dynamic contrast-enhanced MR imaging in assessment of antiangiogenic therapy. , 2010, Radiology.

[23]  Susan M. Chang,et al.  Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02). , 2010, Neuro-oncology.

[24]  R. Gilbertson,et al.  Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  J. Hennig,et al.  A phase IA, open-label, dose-escalating study of PTK787/ZK 222584 administered orally on a continuous dosing schedule in patients with advanced cancer. , 2010, Anticancer research.

[26]  J. Heymach,et al.  Interim safety and pharmacodynamic results for ALN-VSP02, a novel RNAi therapeutic for solid tumors with liver involvement. , 2010 .

[27]  A. Heerschap,et al.  Assessment of early vascular effects of the angiogenesis inhibitor sunitinib (SU) in renal cell carcinoma (RCC) by dynamic contrast enhanced MRI (DCE-MRI) and diffusion weight MRI (DWI) at 3 tesla (T). , 2010 .

[28]  Anwar R. Padhani,et al.  Perfusion MRI in the early clinical development of antivascular drugs: decorations or decision making tools? , 2010, European Journal of Nuclear Medicine and Molecular Imaging.

[29]  M. Knopp,et al.  Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  A. Testori,et al.  Large randomized study of thymosin alpha 1, interferon alfa, or both in combination with dacarbazine in patients with metastatic melanoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  D. Camidge,et al.  Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  D. Lacombe,et al.  Phase I Clinical and Magnetic Resonance Imaging Study of the Vascular Agent NGR-hTNF in Patients with Advanced Cancers (European Organization for Research and Treatment of Cancer Study 16041) , 2010, Clinical Cancer Research.

[33]  S. Steinberg,et al.  Vandetanib, Designed to Inhibit VEGFR2 and EGFR Signaling, Had No Clinical Activity as Monotherapy for Recurrent Ovarian Cancer and No Detectable Modulation of VEGFR2 , 2010, Clinical Cancer Research.

[34]  Lawrence H. Schwartz,et al.  Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  S. Robinson,et al.  Native T 1 is a Generic Imaging Biomarker of Response to Chemotherapy in Neuroblastoma , 2010 .

[36]  J. Machiels,et al.  Phase II study of sunitinib in recurrent or metastatic squamous cell carcinoma of the head and neck: GORTEC 2006-01. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  P. Scifo,et al.  Defining the optimal biological dose of NGR-hTNF, a selective vascular targeting agent, in advanced solid tumours. , 2010, European journal of cancer.

[38]  D. J. Collins,et al.  Evaluating the Early Effects of Anti-angiogenic Treatment in human breast cancer with Intrinsic susceptibility-weighted and Diffusion-weighted MRI : initial observations , 2010 .

[39]  R. Kaiser,et al.  Phase I Study of the Angiogenesis Inhibitor BIBF 1120 in Patients with Advanced Solid Tumors , 2009, Clinical Cancer Research.

[40]  D. Vriens,et al.  Chemotherapy Response Monitoring of Colorectal Liver Metastases by Dynamic Gd-DTPA–Enhanced MRI Perfusion Parameters and 18F-FDG PET Metabolic Rate , 2009, Journal of Nuclear Medicine.

[41]  Geoff J M Parker,et al.  Quantifying Antivascular Effects of Monoclonal Antibodies to Vascular Endothelial Growth Factor: Insights from Imaging , 2009, Clinical Cancer Research.

[42]  Neeraj Gupta,et al.  Phase I and biomarker study of ABT-869, a multiple receptor tyrosine kinase inhibitor, in patients with refractory solid malignancies. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  J. Hennig,et al.  DCE-MRI assessment of the effect of vandetanib on tumor vasculature in patients with advanced colorectal cancer and liver metastases: a randomized phase I study , 2009, Journal of angiogenesis research.

[44]  J. Bloem,et al.  Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  Jenghwa Chang,et al.  Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas. , 2009, International journal of radiation oncology, biology, physics.

[46]  Martin O. Leach,et al.  Reproducibility and changes in the apparent diffusion coefficients of solid tumours treated with combretastatin A4 phosphate and bevacizumab in a two-centre phase I clinical trial , 2009, European Radiology.

[47]  Marek Ancukiewicz,et al.  Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  E. Merkle,et al.  Phase I Trial of Pazopanib in Patients with Advanced Cancer , 2009, Clinical Cancer Research.

[49]  J. Jesberger,et al.  A Vasculature-Targeting Regimen of Preoperative Docetaxel with or without Bevacizumab for Locally Advanced Breast Cancer: Impact on Angiogenic Biomarkers , 2009, Clinical Cancer Research.

[50]  Jiachao Liang,et al.  Phase II trial of sorafenib in metastatic thyroid cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  R. Cox,et al.  Acute Effects of Bevacizumab on Glioblastoma Vascularity Assessed with DCE-MRI and Relation to Patient Survival , 2009 .

[52]  Avraham Eisbruch,et al.  Early prediction of outcome in advanced head-and-neck cancer based on tumor blood volume alterations during therapy: a prospective study. , 2008, International journal of radiation oncology, biology, physics.

[53]  D. Strumberg,et al.  Phase I dose escalation study of telatinib (BAY 57-9352) in patients with advanced solid tumours , 2008, British Journal of Cancer.

[54]  E. Rofstad,et al.  Limitations of dynamic contrast‐enhanced MRI in monitoring radiation‐induced changes in the fraction of radiobiologically hypoxic cells in human melanoma xenografts , 2008, Journal of magnetic resonance imaging : JMRI.

[55]  Gregory Karczmar,et al.  Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  S. Rafii,et al.  Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[57]  K. Flaherty,et al.  Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma , 2008, Cancer biology & therapy.

[58]  A. Wozniak,et al.  Phase I clinical evaluation of ZD6126, a novel vascular-targeting agent, in patients with solid tumors , 2008, Investigational New Drugs.

[59]  K. Davies,et al.  Phase I Evaluation of CDP791, a PEGylated Di-Fab′ Conjugate that Binds Vascular Endothelial Growth Factor Receptor 2 , 2007, Clinical Cancer Research.

[60]  J. Griffiths,et al.  Assessment of tumor response to the vascular disrupting agents 5,6-dimethylxanthenone-4-acetic acid or combretastatin-A4-phosphate by intrinsic susceptibility magnetic resonance imaging. , 2007, International journal of radiation oncology, biology, physics.

[61]  Michael L Maitland,et al.  Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer. , 2007, Journal of the National Cancer Institute.

[62]  J. Lewin,et al.  Inflammatory Breast Cancer as a Model Disease to Study Tumor Angiogenesis: Results of a Phase IB Trial of Combination SU5416 and Doxorubicin , 2007, Clinical Cancer Research.

[63]  Lawrence Barnthouse,et al.  Issues and Recommendations , 2007 .

[64]  J. Drevs,et al.  Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[65]  M. Schabel,et al.  A randomized phase 2 trial of combretatstatin A4 phosphate (CA4P) in combination with paclitaxel and carboplatin to evaluate safety and efficacy in subjects with advanced imageable malignancies , 2007 .

[66]  S. Steinberg,et al.  Dual targeting of vascular endothelial growth factor (VEGF) with sorafenib and bevacizumab: Clinical and translational results , 2007 .

[67]  Mark A. Horsfield,et al.  Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) as a biomarker for the effect of PTK787/ZK 222584 (PTK/ZK) as second-line mono-therapy in patients with stage IIIB or stage IV non-small cell lung cancer (NSCLC) , 2007 .

[68]  C. Takimoto,et al.  A phase I study of AEE788, a multitargeted inhibitor of ErbB and VEGF receptor family tyrosine kinases, to determine safety, PK and PD in patients (pts) with advanced colorectal cancer (CRC) and liver metastases , 2007 .

[69]  Geoff J M Parker,et al.  Imaging Tumor Vascular Heterogeneity and Angiogenesis using Dynamic Contrast-Enhanced Magnetic Resonance Imaging , 2007, Clinical Cancer Research.

[70]  R. Herbst,et al.  Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[71]  G. Parker,et al.  DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents , 2007, British Journal of Cancer.

[72]  Tracy T Batchelor,et al.  AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. , 2007, Cancer cell.

[73]  J. Manson,et al.  Prospective Study of , 2007 .

[74]  Mark J. Ratain,et al.  Measuring response in a post-RECIST world: from black and white to shades of grey , 2006, Nature Reviews Cancer.

[75]  Peter Smeets,et al.  Noninvasive monitoring of radiotherapy-induced microvascular changes using dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) in a colorectal tumor model. , 2006, International journal of radiation oncology, biology, physics.

[76]  M. Ravic,et al.  5,6-Dimethylxanthenone-4-Acetic Acid in the Treatment of Refractory Tumors: a Phase I Safety Study of a Vascular Disrupting Agent , 2006, Clinical Cancer Research.

[77]  Kevin Camphausen,et al.  Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[78]  D. Collins,et al.  Dynamic MRI evaluation of the triple receptor tyrosine kinase inhibitor BIBF 1120 in patients with advanced solid tumours , 2006 .

[79]  Philippe Lambin,et al.  Dynamic contrast-enhanced magnetic resonance imaging of radiation therapy-induced microcirculation changes in rectal cancer. , 2005, International journal of radiation oncology, biology, physics.

[80]  J. Lewin,et al.  Novel Phase I Dose De-escalation Design Trial to Determine the Biological Modulatory Dose of the Antiangiogenic Agent SU5416 , 2005, Clinical Cancer Research.

[81]  A. Padhani,et al.  Effects of platinum/taxane based chemotherapy on acute perfusion in human pelvic tumours measured by dynamic MRI , 2005, British Journal of Cancer.

[82]  A. Padhani,et al.  A Phase I study of the angiogenesis inhibitor SU5416 (semaxanib) in solid tumours, incorporating dynamic contrast MR pharmacodynamic end points , 2005, British Journal of Cancer.

[83]  Benjamin M Yeh,et al.  Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[84]  Eric Masson,et al.  Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[85]  Jürgen Hennig,et al.  Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumours. , 2005, European journal of cancer.

[86]  M. Knopp,et al.  The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations , 2005, British Journal of Cancer.

[87]  Catherine Wheeler,et al.  A Multicenter Phase II Trial of ZD6474, a Vascular Endothelial Growth Factor Receptor-2 and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients with Previously Treated Metastatic Breast Cancer , 2005, Clinical Cancer Research.

[88]  G. Sledge,et al.  What is targeted therapy? , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[89]  J. Provenzale,et al.  A phase I/II trial of single-agent PTK 787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in patients with recurrent glioblastoma multiforme (GBM). , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[90]  Milica Medved,et al.  Semiquantitative analysis of dynamic contrast enhanced MRI in cancer patients: Variability and changes in tumor tissue over time , 2004, Journal of magnetic resonance imaging : JMRI.

[91]  P. Thorpe.  Vascular Targeting Agents as Cancer Therapeutics , 2004, Clinical Cancer Research.

[92]  Weijing Sun,et al.  Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[93]  Lee M Ellis,et al.  Antiangiogenic therapy: more promise and, yet again, more questions. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[94]  Jerry M Collins,et al.  Functional imaging in phase I studies: decorations or decision making? , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[95]  Martin A Lodge,et al.  Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[96]  N. Ferrara,et al.  The biology of VEGF and its receptors , 2003, Nature Medicine.

[97]  T. Ng,et al.  A phase I study of anti-kinase insert domain-containing receptor antibody, IMC-1C11, in patients with liver metastases from colorectal carcinoma. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[98]  A. Jackson,et al.  Reproducibility of quantitative dynamic contrast-enhanced MRI in newly presenting glioma. , 2003, The British journal of radiology.

[99]  Jamal Zweit,et al.  Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: implications for trial design of antiangiogenic antibodies. , 2002, Journal of the National Cancer Institute.

[100]  A. Padhani,et al.  Effects of 5,6-dimethylxanthenone-4-acetic acid on human tumor microcirculation assessed by dynamic contrast-enhanced magnetic resonance imaging. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[101]  Donald W Kufe,et al.  Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[102]  J. Lewin,et al.  A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. , 2002, Cancer research.

[103]  A. Padhani,et al.  Reproducibility of dynamic contrast‐enhanced MRI in human muscle and tumours: comparison of quantitative and semi‐quantitative analysis , 2002, NMR in biomedicine.

[104]  A. Padhani,et al.  Assessing changes in tumour vascular function using dynamic contrast‐enhanced magnetic resonance imaging , 2002, NMR in biomedicine.

[105]  David L Buckley,et al.  Uncertainty in the analysis of tracer kinetics using dynamic contrast‐enhanced T1‐weighted MRI , 2002, Magnetic resonance in medicine.

[106]  M. Ducreux,et al.  A phase II study: docetaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma. , 2000, European journal of cancer.

[107]  J. Abedi.  Issues and recommendations concerning COVID-19 vaccine rollout The Independent SAGE Report 25 , 2000 .

[108]  M. Knopp,et al.  Estimating kinetic parameters from dynamic contrast‐enhanced t1‐weighted MRI of a diffusable tracer: Standardized quantities and symbols , 1999, Journal of magnetic resonance imaging : JMRI.

[109]  H. Niitani,et al.  [Phase II study]. , 1995, Gan to kagaku ryoho. Cancer & chemotherapy.

[110]  P. Tofts,et al.  Measurement of the blood‐brain barrier permeability and leakage space using dynamic MR imaging. 1. Fundamental concepts , 1991, Magnetic resonance in medicine.